Learning objective:         

After joining this meeting, participants should be able to:

• Describe the clinical benefits of earlier treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) and the consequences of disease progression
• Discuss the impact of new data on treatment and management decisions for ...

Learning objectives:         

After watching this broadcast, participants should be able to:

• Discuss and explain the new data on prostate cancer
• Discuss how the new data will affect daily clinical practice

Scientific committee:

• Heather Payne, UK
• Kurt Miller, Germany

Learning objectives:         

After watching this broadcast, participants should be able to:

• Discuss and explain the new data on prostate cancer
• Discuss how the new data will affect daily clinical practice

Scientific committee:

• Heather Payne, UK
• Kurt Miller, Germany

Learning objective:         

After watching this broadcast, participants should be able to:

• Evaluate the management options for advanced prostate cancer patients during the current COVID-19 pandemic
• Discuss the impact of the COVID-19 pandemic on patients and HCPs

Scientific committee:

• Heather Payne, UK
• Kurt Miller, Germany

Learning objectives:

After attending this meeting, participants should be able to:

• Discuss ongoing changes and the subsequent impact on the treatment landscape of advanced prostate cancer
• Review advances in therapeutic strategies for mHSPC
• Explore practical management of treatment options in nmCRPC

Faculty:

Learning objectives:

After attending this meeting, participants should be able to:

• Differentiate current metastatic urothelial carcinoma treatment options and describe their applicability in clinical practice
• Evaluate tumour biology, the role of biomarkers, and the challenges of advanced urothelial carcinoma from a multidisciplinary perspective
• Describe how current research may drive therapeutic decisions for patients with advanced urothelial ...